StreetInsider.com News Articles

Form 6-K Evaxion A/S For: Jun 12

Fri, 12 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260612/26637896.html

Form 6-K Evaxion A/S For: Jun 12

Fri, 12 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260612/26637896.html

Evaxion receives Prix Galien UK Award for Best digital health solution

Fri, 12 Jun 2026 03:00:00 -0400

COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has been awarded the 2026 Prix Galien UK Award for Best digital health solution for AI-Immunology™.

The award is another strong external validation and recognition of the AI-Immunology™ platform, which harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

The award was received by Evaxion CEO Helen-Tayton Martin at the Prix Galien UK Awards ceremony at the Natural History

Evaxion receives Prix Galien UK Award for Best digital health solution

Fri, 12 Jun 2026 03:00:00 -0400

The award was received by Evaxion CEO Helen-Tayton Martin at the Prix Galien UK Awards ceremony at the Natural History

Form 6-K Evaxion A/S For: Jun 11

Thu, 11 Jun 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260611/26632129.html

Form 6-K Evaxion A/S For: Jun 11

Thu, 11 Jun 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260611/26632129.html

Evaxion presents preclinical data for acute myeloid leukemia vaccine

Thu, 11 Jun 2026 02:00:31 -0400

Evaxion A/S (NASDAQ: EVAX) announced preclinical data for EVX-04, a therapeutic vaccine candidate for acute myeloid leukemia. The company will present the data at the European Hematology Association Congress in Stockholm on June 13, 2026.

According to the company, EVX-04 demonstrated complete expression in human cells, including transcription and translation. The vaccine candidate is secreted in human cells, which the company states enables immune recognition and activation.

The data showed that all endogenous retrovirus antigens included in EVX-04 generated specific immune responses in both mouse and human cell studies across different human immune profiles. The vaccine-induced immune cells demonstrated targeted cell-killing activity.

EVX-04

Evaxion presents preclinical data for acute myeloid leukemia vaccine

Thu, 11 Jun 2026 02:00:31 -0400

EVX-04

Evaxion presents preclinical data for leukemia vaccine candidate

Thu, 11 Jun 2026 02:00:14 -0400

Evaxion A/S (NASDAQ: EVAX) announced preclinical data for EVX-04, an experimental therapeutic vaccine for acute myeloid leukemia. The Copenhagen-based biotechnology company said the vaccine candidate demonstrated complete expression and secretion in human cells, enabling immune recognition and activation.

The company reported that all endogenous retrovirus antigens included in EVX-04 generated specific immune responses in both mouse models and human cells across different immune profiles. The vaccine-induced immune cells showed targeted cell-killing capabilities in laboratory tests.

EVX-04 was developed using Evaxion's AI-Immunology platform, which identified 16 optimal endogenous retrovirus fragments from five million discovered fragments. These antigens target tumor-specific markers absent in normal

Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia